NCT05776407 - Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

November 30, 2024

Conditions

Refractory or Relapsed B Cell Lymphoma

Interventions

DRUG

ThisCART19A

Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.

DRUG

Fludarabine

Fludarabine is used for lymphodepletion.

DRUG

Cyclophosphamide

Cyclophosphamide is used for lymphodepletion.

DRUG

Etoposide

Etoposide is used for lymphodepletion.

Trial Locations (1)

400030

Chongqing University Cancer Hospital, Chongqing